ACADIA PHARMACEUTICALS INC (ACAD)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 400M 800M 1.2B Q4 '10: 42.1M Q1 '11: 40.4M Q2 '11: 38.6M Q3 '11: 36.9M Q4 '11: 2.1M Q1 '12: 2.1M Q2 '12: 2.2M Q3 '12: 5.1M Q4 '12: 4.9M Q1 '13: 4.9M Q2 '13: 4.7M Q3 '13: 1.5M Q4 '13: 1.1M Q1 '14: 758K Q2 '14: 335K Q3 '14: 110K Q4 '14: 120K Q1 '15: 94K Q2 '15: 67K Q3 '15: 91K Q4 '15: 61K Q1 '16: 61K Q2 '16: 157K Q3 '16: 5.4M Q4 '16: 17.3M Q1 '17: 32.6M Q2 '17: 63M Q3 '17: 93.3M Q4 '17: 124.9M Q1 '18: 158.5M Q2 '18: 185.1M Q3 '18: 207.8M Q4 '18: 223.8M Q1 '19: 237.9M Q2 '19: 264M Q3 '19: 300.3M Q4 '19: 339.1M Q1 '20: 366.2M Q2 '20: 393.1M Q3 '20: 419.1M Q4 '20: 441.8M Q3 '21: 474.4M Q4 '21: 484.1M Q1 '22: 493.1M Q2 '22: 512.4M Q3 '22: 511.5M Q4 '22: 517.2M Q1 '23: 520.2M Q2 '23: 550.9M Q3 '23: 631.9M Q4 '23: 726.4M Q1 '24: 813.8M Q2 '24: 890.5M Q3 '24: 929.2M Q4 '24: 957.8M Q1 '25: 996.3M Q2 '25: 1B Q3 '25: 1B Q4 '25: 1.1B Q1 '26: 1.1B Q2 '26: 1.1B Q4 '11 Q4 '13 Q4 '15 Q4 '17 Q4 '19 Q2 '22 Q2 '24 Q2 '26

Gross Profit TTM

0 250M 500M 750M Q4 '16: 14.3M Q1 '17: 27.3M Q2 '17: 56M Q3 '17: 85M Q4 '17: 115.8M Q1 '18: 149.5M Q2 '18: 174.8M Q3 '18: 195.8M Q4 '18: 211.4M Q1 '19: 224.7M Q2 '19: 251.5M Q3 '19: 289.2M Q4 '19: 327.7M Q1 '20: 355M Q2 '20: 381.9M Q3 '20: 408.4M Q4 '20: 431.5M Q1 '21: 448.6M Q2 '21: 454.1M Q3 '21: 463.5M Q4 '21: 473.3M Q1 '22: 481.5M Q2 '22: 500.7M Q3 '22: 501.3M Q4 '22: 507.1M Q1 '23: 511.3M Q2 '23: 537.2M Q3 '23: 605.7M Q4 '23: 684.8M Q4 '16 Q4 '17 Q4 '18 Q4 '19 Q4 '20 Q4 '21 Q4 '22 Q4 '23

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '10: 15.1M Q1 '11: 14.7M Q2 '11: 12.4M Q3 '11: 11.6M Q4 '11: -22.9M Q1 '12: -23.2M Q2 '12: -22.1M Q3 '12: -19.4M Q4 '12: -20.9M Q1 '13: -20.8M Q2 '13: -24.5M Q3 '13: -33M Q4 '13: -38.3M Q1 '14: -50.1M Q2 '14: -62.7M Q3 '14: -76.8M Q4 '14: -93.2M Q1 '15: -115.8M Q2 '15: -133.6M Q3 '15: -147.6M Q4 '15: -164.6M Q1 '16: -174.3M Q2 '16: -206.7M Q3 '16: -240.1M Q4 '16: -272.8M Q1 '17: -311.3M Q2 '17: -307.4M Q3 '17: -300.6M Q4 '17: -292.4M Q1 '18: -258.5M Q2 '18: -254.6M Q3 '18: -250.2M Q4 '18: -247.4M Q1 '19: -280.3M Q2 '19: -273.3M Q3 '19: -257.4M Q4 '19: -246.5M Q1 '20: -248.4M Q2 '20: -235.3M Q3 '20: -275.8M Q4 '20: -286.6M Q1 '21: -263.8M Q2 '21: -263.5M Q3 '21: -192.9M Q4 '21: -170.4M Q1 '22: -216.7M Q2 '22: -206.6M Q3 '22: -222.2M Q4 '22: -223.6M Q1 '23: -164.2M Q2 '23: -127.5M Q3 '23: -154.4M Q4 '23: -73.4M Q1 '24: -4.6M Q2 '24: 22.8M Q3 '24: 112.2M Q4 '24: 230.8M Q1 '25: 234.9M Q2 '25: 236.8M Q3 '25: 240.9M Q4 '25: 104.8M Q1 '26: 80.9M Q2 '26: 86.4M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Net Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '10: 15.1M Q1 '11: 14.8M Q2 '11: 12.5M Q3 '11: 11.7M Q4 '11: -22.8M Q1 '12: -23.1M Q2 '12: -22M Q3 '12: -19.3M Q4 '12: -20.8M Q1 '13: -20.8M Q2 '13: -24.4M Q3 '13: -32.7M Q4 '13: -37.9M Q1 '14: -49.7M Q2 '14: -62.1M Q3 '14: -76.2M Q4 '14: -92.5M Q1 '15: -115M Q2 '15: -132.9M Q3 '15: -147M Q4 '15: -164.4M Q1 '16: -173.8M Q2 '16: -205.8M Q3 '16: -238.5M Q4 '16: -271.4M Q1 '17: -309.5M Q2 '17: -305.6M Q3 '17: -299.2M Q4 '17: -289.4M Q1 '18: -255.9M Q2 '18: -251.7M Q3 '18: -248.6M Q4 '18: -245.2M Q1 '19: -276.2M Q2 '19: -267.9M Q3 '19: -247.7M Q4 '19: -235.3M Q1 '20: -238M Q2 '20: -225.2M Q3 '20: -267.9M Q4 '20: -281.6M Q3 '21: -191.5M Q4 '21: -167.9M Q1 '22: -214.5M Q2 '22: -204.6M Q3 '22: -217.3M Q4 '22: -216M Q1 '23: -145.9M Q2 '23: -110.8M Q3 '23: -148.8M Q4 '23: -61.3M Q1 '24: -1.7M Q2 '24: 30.6M Q3 '24: 128.5M Q4 '24: 226.5M Q1 '25: 228.9M Q2 '25: 222.2M Q3 '25: 261.2M Q4 '25: 391M Q1 '26: 375.6M Q2 '26: 380.5M Q4 '11 Q4 '13 Q4 '15 Q4 '17 Q4 '19 Q2 '22 Q2 '24 Q2 '26

Cost of Revenue TTM

0 35M 70M 105M Q4 '17: 9.1M Q1 '18: 9M Q2 '18: 10.3M Q3 '18: 12M Q4 '18: 12.4M Q1 '19: 13.2M Q2 '19: 12.6M Q3 '19: 11.1M Q4 '19: 11.3M Q1 '20: 11.2M Q2 '20: 11.1M Q3 '20: 10.7M Q4 '20: 10.2M Q1 '21: 9.6M Q2 '21: 9.2M Q3 '21: 10.9M Q4 '21: 19.1M Q1 '22: 19.9M Q2 '22: 20M Q3 '22: 18.5M Q4 '22: 10.2M Q1 '23: 8.9M Q2 '23: 13.7M Q3 '23: 26.2M Q4 '23: 41.6M Q1 '24: 62.9M Q2 '24: 73.7M Q3 '24: 77.9M Q4 '24: 81.8M Q1 '25: 79.3M Q2 '25: 81.8M Q3 '25: 84.6M Q4 '25: 89M Q1 '26: 93.4M Q2 '26: 101M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q4 '11: -19.9M Q1 '12: -20M Q2 '12: -19.5M Q3 '12: -20.7M Q4 '12: -21.6M Q1 '13: -23M Q2 '13: -23.6M Q3 '13: -27.8M Q4 '13: -31.8M Q1 '14: -39.4M Q2 '14: -50.9M Q3 '14: -58.9M Q4 '14: -66.4M Q1 '15: -77.6M Q2 '15: -90.5M Q3 '15: -104.9M Q4 '15: -121.8M Q1 '16: -137.7M Q2 '16: -164.5M Q3 '16: -181.9M Q4 '16: -210.4M Q1 '17: -239.8M Q2 '17: -242M Q3 '17: -251.2M Q4 '17: -217.9M Q1 '18: -192.5M Q2 '18: -174.4M Q3 '18: -158.3M Q4 '18: -167.5M Q1 '19: -186.4M Q2 '19: -183.9M Q3 '19: -160.5M Q4 '19: -151.1M Q1 '20: -136M Q2 '20: -134.4M Q3 '20: -138.4M Q4 '20: -136.2M Q1 '21: -147.3M Q2 '21: -135.8M Q3 '21: -130M Q4 '21: -125.7M Q1 '22: -141.8M Q2 '22: -129.6M Q3 '22: -113.3M Q4 '22: -114M Q1 '23: -55.6M Q2 '23: -34.3M Q3 '23: -92.5M Q4 '24: 157.7M Q1 '25: 149M Q2 '25: 187.9M Q3 '25: 198.9M Q2 '12 Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '25

Free Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q2 '14: -51.4M Q3 '14: -59.1M Q4 '14: -66.6M Q1 '15: -78.8M Q2 '15: -92.3M Q3 '15: -106.8M Q4 '15: -123.9M Q1 '16: -139M Q2 '16: -165.8M Q3 '16: -183.5M Q4 '16: -211.9M Q1 '17: -241.5M Q2 '17: -243.5M Q3 '17: -252.2M Q4 '17: -218.7M Q1 '18: -193.3M Q2 '18: -175M Q3 '18: -159.9M Q4 '18: -169.6M Q1 '19: -188.9M Q2 '19: -186.3M Q3 '19: -161.9M Q4 '19: -152.3M Q1 '20: -137.2M Q2 '20: -138.6M Q3 '20: -144.2M Q4 '20: -143.8M Q1 '21: -155M Q2 '21: -140.6M Q3 '21: -133.1M Q4 '21: -126.8M Q1 '22: -141.9M Q2 '22: -129.6M Q3 '22: -113.3M Q4 '22: -114M Q2 '25: 187.1M Q3 '25: 197.8M Q3 '14 Q4 '15 Q1 '17 Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q3 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 60M 120M 180M Q2 '21: 160.4K Q3 '21: 160.7K Q1 '22: 161.2M Q2 '22: 161.7K Q3 '22: 161.9K Q1 '23: 162.3M Q2 '23: 165M Q3 '23: 164.2M Q1 '24: 166.6M Q2 '24: 166.2M Q3 '24: 166.2M Q1 '25: 167.7M Q2 '25: 168.7M Q3 '25: 170.7M Q1 '26: 172.7M Q2 '26: 172.9M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.70 -1.80 -0.90 0.00 0.90 1.80 2.70 Q4 '11: -0.44 Q1 '12: -0.44 Q2 '12: -0.42 Q3 '12: -0.36 Q4 '12: -0.37 Q1 '13: -0.33 Q2 '13: -0.34 Q3 '13: -0.42 Q4 '13: -0.44 Q1 '14: -0.55 Q2 '14: -0.66 Q3 '14: -0.79 Q4 '14: -0.94 Q1 '15: -1.15 Q2 '15: -1.32 Q3 '15: -1.46 Q4 '15: -1.63 Q1 '16: -1.68 Q2 '16: -1.92 Q3 '16: -2.14 Q4 '16: -2.34 Q1 '17: -2.61 Q2 '17: -2.53 Q3 '17: -2.45 Q4 '17: -2.35 Q1 '18: -2.07 Q2 '18: -2.03 Q3 '18: -2.00 Q4 '18: -1.95 Q1 '19: -2.10 Q2 '19: -1.97 Q3 '19: -1.76 Q4 '19: -1.60 Q1 '20: -1.58 Q2 '20: -1.47 Q3 '20: -1.72 Q4 '20: -1.80 Q3 '23: -0.92 Q4 '23: -0.38 Q1 '24: -0.01 Q2 '24: 0.18 Q3 '24: 0.78 Q4 '24: 1.36 Q1 '25: 1.37 Q2 '25: 1.33 Q3 '25: 1.55 Q4 '25: 2.30 Q1 '26: 2.21 Q2 '26: 2.23 Q2 '13 Q1 '15 Q4 '16 Q3 '18 Q2 '20 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.